SpainSpain

Spanish start up to develop therapeutic HPV vaccine

18.06.2008

A Madrid – About 70% of all women will become infected with papilloma viruses (HPV) at least once in their lifetime. Now, the Spanish vaccine specialist Chimera Pharma SL (Madrid) has signed an exclusive licensing and cooperation agreement with the German Cancer Research Centre (DKFZ) in Heidelberg. Under the agreement, the two partners will develop, a therapeutic vaccine against cervical cancer to prevent women who are already infected with HPV from developing cancer, and to eradicate existing cancer prestages. Chimera has got exclusive world-wide rights to commercialise thevaccine.

Huge market promise

The market for a vaccine that kills the cancer-causing virus subtypes seems to be extremely promising. Sanofi-Pasteur MSD, which licensed IP from Chimera’s German cooperation partners under Prof. Harald zur Hausen and Dr. Angel Cid-Arregui, has made EUR1.3bn revenues with the prophylactic HPV vaccine Gardasil® since its market launch in June 2006.
Together with our Spanish partners, we will develop a protein vaccine against HPV16 and HPV18, which are linked to cervical cancer,” Cid-Arregui told EuroBiotechNews. The vaccine will be based on fusion proteins of three HPV envelope protein domains with the HBSAg envelope protein of the Hepatitis-B virus, which forms empty immunogenic virus envelopes. In addition to this, the virus shells can transport further proteins that stimulate the immune system.
“Similar to our patented (US-PTO 7,201,908) vaccine candidate, we have demonstrated the preclinical efficacy of our new compound,” says Cid-Arregui. The young Spanish company – part of Madrid-based Grupo Bionostra – is currently beginning toxicological studies, and is planning to establish GMP production by February, and to file an application for clinical development by summer 2009. Like many biotech companies that develop compounds to Phase 2 for outlicensing to big pharma, Chimera currently does not have the resources for full clinical development. Thus, at the moment outlicencing to a big pharma company seems the most probable exit

SpainSpain

08.06.2010

Barcelona/Triangle Park – Spanish producer of plasma protein therapies Grifols is to acquire US public biopharmaceutical company Talecris, in a deal worth approximately $3.4 billion (EUR2.8 billion). The merger will improve...

SpainSpain

12.05.2010

Madrid – In the last few years, the number of companies interested in mining marine life for interesting substances has risen steadily. Madrid-based Pharmamar was one of the first, and is also one of the very few to have a...

SpainSpain

11.05.2010

Pamplona – From Sept. 29th-Oct. 1st, Pamplona will become the centre of the European biotechnology world when the city famous for the annual running of the bulls through the medieval town centre hosts the BioSpain 2010. The...

SpainSpain

07.03.2010

San Sebastian – Europe has to unify its research efforts and infrastructures if it doesn’t want to be overtaken by Asian competitors such as China in the mid-term – that was Spanish Science Minister Cristina Garmendia’s message...

SpainSpain

07.03.2010

Madrid/Rockville – Spain’s Rovi Pharmaceuticals has terminated talks with US vaccine specialist Novavax Inc. to license recombinant virus-like particle (VLP) vaccine technology to help Spain meet its seasonal and pandemic flu...

SpainSpain

01.02.2010

Barcelona – Ferrer inCode has agreed to distribute DiaGenic’s blood-based ADtect test for the early diagnosis of Alzheimer’s Disease. The agreement with the Oslo-based company gives Ferrer inCode, a biotech subsidiary of Grupo...

SpainSpain

01.02.2010

Seville – Scientists at the University of Seville have published the first demographic map of colon cancer in Spain. The analysis examines Spanish trends between 1951-2006 in terms of particular changes in consumption patterns...

SpainSpain

01.02.2010

Madrid – A goundbreaking technique that promised to speed up the discovery of novel microbial enzymes from environmental samples has come in for criticism. Soon after scientists from Spain, Germany, and the UK had presented their...

SpainSpain

27.11.2009

Barcelona/Heidelberg – US genome pioneer Craig Venters’ plan to create a minimal synthetic cell based on the essential genes of Mycoplasma bacteria may ultimately be too ambitious. A brand new study conducted by a team of...

Displaying results 31 to 40 out of 181

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/3/article/spanish-start-up-to-develop-therapeutic-hpv-vaccine.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.84 EUR4.80%
  • VITA 343.98 EUR4.19%
  • MEDIGENE4.07 EUR2.26%

FLOP

  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.24 CHF-4.00%
  • BASILEA97.25 CHF-1.22%

TOP

  • SANTHERA93.80 CHF46.3%
  • CO.DON2.84 EUR19.3%
  • FORMYCON8.22 EUR18.8%

FLOP

  • EVOTEC3.09 EUR-17.6%
  • MEDIGENE4.07 EUR-13.8%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA93.80 CHF2036.7%
  • CO.DON2.84 EUR226.4%
  • PAION2.69 EUR158.7%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.08 CHF-46.7%
  • MERCK KGAA67.56 EUR-41.3%

No liability assumed, Date: 15.09.2014


Current issue

All issues

Product of the week

Products